with a market valuation of 41,515.55 Cr, Zydus Lifesciences Ltd. Ltd. is a large-cap business that operates in the pharmaceutical industry. With its headquarters in Ahmedabad, India, Zydus Group is the fourth ranked pharmaceutical company in the country. The group has production and research facilities in five Indian states—Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim—as well as in the US and Brazil.
Today the US Food and Drug Administration (USFDA) has approved Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (USRLD: Vivelle-Dot® Transdermal System) . The company announced that estradiol transdermal system is indicated to treat moderate to severe symptoms of menopause, including a feeling of warmth in the face, neck, and chest or sudden onset of hot flashes, hot flashes, and vaginal dryness in women. is included. The drug will be manufactured at the group’s manufacturing facility in Moraiya, Ahmedabad, India. Since the filing process began in fiscal year 2003–04, the organization has filed 431* ANDAs, and now has 336 approvals.
The United States Food and Drug Administration (USFDA) granted Zydus Lifesciences Limited approval for marketing yesterday, December 1, for Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg (USRLD: Qudexy® XR). Final permission granted. extended-release capsules). According to IQVIA data, annual sales for topiramate extended-release capsules were US$68.8 million in the United States (IQVIA MAT Sep 2022). Since the filing process began in fiscal year 2003–04, the organization has filed 431* ANDAs, and now has 335 approvals. The company announced that Topiramate Extended-Release Capsules is indicated to prevent and control seizures in people with epilepsy. It can also be used to prevent migraine headaches. The drug will be manufactured at the group’s manufacturing facility in Ahmedabad SEZ, India.
Zydus Lifesciences on Tuesday disclosed that it has signed a business transfer agreement to acquire the Active Pharmaceutical Ingredients (API) business of Watson Pharma for a one-time payment. 46.77 crore, free of cash and debt. The acquisition is expected to close by March 31, 2023, and Watson’s business venture is in the business of producing, manufacturing, marketing and selling active pharmaceutical ingredients (“APIs”).
Zydus Lifesciences shares open today 410.00 each and currently, it is trading at market value of 411.05 with a negative margin of 0.06%. On YTD basis, the stock has declined 13.92% so far in 2022.
catch all corporate news And updates on Live Mint. download mint news app to receive daily market update & Live business News,